A single bout of vigorous intensity exercise enhances the efficacy of rituximab against autologous human chronic lymphocytic leukaemia B-cells ex vivo
Brain Behav Immun. 2024 Mar 17:S0889-1591(24)00304-0. doi: 10.1016/j.bbi.2024.03.023. Online ahead of print.ABSTRACTChronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal antibody immunotherapy. Rituximab often fails to induce stringent disease eradication, due in part to failure of antibody-dependent cellular cytotoxicity which relies on natural killer (NK)-cells binding to rituximab-bound CD20 on B-cells. CLL cells are diffusely spread across lymphoid and other bodily tissues, and ADCC resistance in s...
Source: Brain, Behavior, and Immunity - March 19, 2024 Category: Neurology Authors: Harrison D Collier-Bain Annabelle Emery Adam J Causer Frankie F Brown Rebecca Oliver David Dutton Josephine Crowe Daniel Augustine John Graby Shoji Leach Rachel Eddy Daniela Rothschild-Rodriguez Juliet C Gray Mark S Cragg Kirstie L Cleary Sally Moore Jame Source Type: research

Utility of ultrasound in the diagnostic approach to lymphoma with splenic involvement
This study highlights the role of abdominal ultrasound as a useful technique in the non-invasive assessment of this entity, considering an appropriate clinical context and mainly after detecting multiple hypoechogenic splenic lesions in the US.PMID:38501803 | DOI:10.17235/reed.2024.10283/2024 (Source: Revista Espanola de Enfermedades Digestivas)
Source: Revista Espanola de Enfermedades Digestivas - March 19, 2024 Category: Gastroenterology Authors: Roc ío Martínez Fernández Lidia Castillo G ázquez Mar ía Caldas Álvarez Leticia Gonz ález Moreno Cecilio Santander Vaquero Source Type: research

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against autologous human chronic lymphocytic leukaemia B-cells ex vivo
Brain Behav Immun. 2024 Mar 17:S0889-1591(24)00304-0. doi: 10.1016/j.bbi.2024.03.023. Online ahead of print.ABSTRACTChronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal antibody immunotherapy. Rituximab often fails to induce stringent disease eradication, due in part to failure of antibody-dependent cellular cytotoxicity which relies on natural killer (NK)-cells binding to rituximab-bound CD20 on B-cells. CLL cells are diffusely spread across lymphoid and other bodily tissues, and ADCC resistance in s...
Source: Brain, Behavior, and Immunity - March 19, 2024 Category: Neurology Authors: Harrison D Collier-Bain Annabelle Emery Adam J Causer Frankie F Brown Rebecca Oliver David Dutton Josephine Crowe Daniel Augustine John Graby Shoji Leach Rachel Eddy Daniela Rothschild-Rodriguez Juliet C Gray Mark S Cragg Kirstie L Cleary Sally Moore Jame Source Type: research

Utility of ultrasound in the diagnostic approach to lymphoma with splenic involvement
This study highlights the role of abdominal ultrasound as a useful technique in the non-invasive assessment of this entity, considering an appropriate clinical context and mainly after detecting multiple hypoechogenic splenic lesions in the US.PMID:38501803 | DOI:10.17235/reed.2024.10283/2024 (Source: Revista Espanola de Enfermedades Digestivas)
Source: Revista Espanola de Enfermedades Digestivas - March 19, 2024 Category: Gastroenterology Authors: Roc ío Martínez Fernández Lidia Castillo G ázquez Mar ía Caldas Álvarez Leticia Gonz ález Moreno Cecilio Santander Vaquero Source Type: research

Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
In Mantle Cell Lymphoma (MCL), the role of macrophages within the tumour microenvironment (TME) has recently gained attention due to their impact on prognosis and response to therapy. Despite their low absolute number in MCL tumour tissue, recent findings reveal an association between the levels of macrophages and prognosis, consistent with trends observed in other lymphoma subtypes. M2-like macrophages, identified by markers such as CD163, contribute to angiogenesis and suppression of the immune response. Clinical trials with MCL patients treated with chemoimmunotherapy and targeted treatments underscore the adverse impac...
Source: Frontiers in Immunology - March 19, 2024 Category: Allergy & Immunology Source Type: research

Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Childrens Cancer Group Multicentre Trial, JPLSG B-NHL-20)
Introduction Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome Malin B (LMB) chemotherapy markedly prolongs event-free survival and overall survival in high-risk patients, the benefit of rituximab in good-risk patients remains to be elucidated. This clinical trial will examine whether the addition of rituximab eliminates anthracyclines in good-risk patients without compromising treatment o...
Source: BMJ Open - March 19, 2024 Category: General Medicine Authors: Sekimizu, M., Fukano, R., Koga, Y., Mitsui, T., Fujita, N., Mori, T., Hori, D., Tanaka, M., Ohki, K., Iwafuchi, H., Nakazawa, A., Mori, T., Kobayashi, R., Hashimoto, H., M. Saito, A., Kamei, M., on behalf of Lymphoma Committee of Japan Childrens Cancer Gr Tags: Open access, Haematology (incl blood transfusion) Source Type: research

ANCA-associated vasculitis presenting with isolated neurological manifestations in a patient with cocaine abuse: a case report and literature review
We present a unique case of AAV with isolated neurological manifestations presenting with multiple cranial neuropathies, leptomeningeal enhancement on imaging and histopathologic evidence of small-vessel vasculitis in the leptomeninges and brain and extensive dural fibrosis in a patient with cocaine abuse. The patient ’s progressive neurological deficits were controlled after starting immunosuppression with rituximab and prednisone. We also reviewed the literature to provide the diagnostic overview of AAV and evaluate intervention options. To our knowledge, this is the first case of AAV with isolated neurologic al manife...
Source: Clinical Rheumatology - March 18, 2024 Category: Rheumatology Source Type: research

Advancements in autoimmune hepatitis management: Perspectives for future guidelines
World J Hepatol. 2024 Feb 27;16(2):135-139. doi: 10.4254/wjh.v16.i2.135.ABSTRACTThe first-line treatment for autoimmune hepatitis involves the use of prednisone or prednisolone either as monotherapy or in combination with azathioprine (AZA). Budesonide has shown promise in inducing a complete biochemical response (CBR) with fewer adverse effects and is considered an optional first-line treatment, particularly for patients without cirrhosis; however, it is worth noting that the design of that study favored budesonide. A recent real-life study revealed higher CBR rates with prednisone when equivalent initial doses were admin...
Source: World Journal of Hepatology - March 18, 2024 Category: Gastroenterology Authors: Marcos Mucenic Source Type: research

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print.ABSTRACTNot available.PMID:38497158 | DOI:10.3324/haematol.2023.284109 (Source: Haematologica)
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Emilio Iannitto Simone Ferrero C ôme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord G Source Type: research

Advancements in autoimmune hepatitis management: Perspectives for future guidelines
World J Hepatol. 2024 Feb 27;16(2):135-139. doi: 10.4254/wjh.v16.i2.135.ABSTRACTThe first-line treatment for autoimmune hepatitis involves the use of prednisone or prednisolone either as monotherapy or in combination with azathioprine (AZA). Budesonide has shown promise in inducing a complete biochemical response (CBR) with fewer adverse effects and is considered an optional first-line treatment, particularly for patients without cirrhosis; however, it is worth noting that the design of that study favored budesonide. A recent real-life study revealed higher CBR rates with prednisone when equivalent initial doses were admin...
Source: World Journal of Hepatology - March 18, 2024 Category: Gastroenterology Authors: Marcos Mucenic Source Type: research

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print.ABSTRACTNot available.PMID:38497158 | DOI:10.3324/haematol.2023.284109 (Source: Haematologica)
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Emilio Iannitto Simone Ferrero C ôme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord G Source Type: research

Advancements in autoimmune hepatitis management: Perspectives for future guidelines
World J Hepatol. 2024 Feb 27;16(2):135-139. doi: 10.4254/wjh.v16.i2.135.ABSTRACTThe first-line treatment for autoimmune hepatitis involves the use of prednisone or prednisolone either as monotherapy or in combination with azathioprine (AZA). Budesonide has shown promise in inducing a complete biochemical response (CBR) with fewer adverse effects and is considered an optional first-line treatment, particularly for patients without cirrhosis; however, it is worth noting that the design of that study favored budesonide. A recent real-life study revealed higher CBR rates with prednisone when equivalent initial doses were admin...
Source: World Journal of Hepatology - March 18, 2024 Category: Gastroenterology Authors: Marcos Mucenic Source Type: research

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print.ABSTRACTNot available.PMID:38497158 | DOI:10.3324/haematol.2023.284109 (Source: Haematologica)
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Emilio Iannitto Simone Ferrero C ôme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord G Source Type: research